CClinicalTrials.gg
RecruitingNCT07344961DANCE AFIBUpdated Feb 4, 2026

Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)

An observational study in Paroxysmal Atrial Fibrillation, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Northwell Health · Observational

From the registry’s dates

  • Started Dec 2025; still recruiting 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, descriptive study. Safety endpoints will not be assessed. All eligible patients that have a history of paroxysmal atrial fibrillation and an indication to undergo Micra AV2 device placement as per standard of care (SOC) across the participating sites within the Northwell Health System can be included in this analysis. Micra AV2 placement indications will be at the discretion of the treating electrophysiologist, but are expected to be predominantly atrioventricular block. Periodic device interrogations will be reviewed for the presence of effective atrial tracking during sinus rhythm . The presence of paroxysmal atrial fibrillation and the degree to which atrial activity and A4 amplitude trend changes will be assessed using a designated Medtronic Research Holter monitor that detects Micra AV2 signals at any point in the study during a episodes of sinus rhythm and atrial fibrillation. Patients who have atrial fibrillation during index hospitalization will undergo placement of the Medtronic Holter monitor as part of the standard of care index hospitalization. Eligible outpatients will undergo placement of the Medtronic Research Holter Monitor in the office.

02

Conditions studied

  • Paroxysmal Atrial Fibrillation

Browse trials for

03

In context

Atrial Fibrillation

3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.

This study's planned enrollment of 50 is below the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Northwell Health is the lead sponsor of 463 studies on the registry; 109 are open to participants now.

Of its 40 completed or terminated interventional studies of FDA-regulated products, 20 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

AFIB patients

Inclusion criteria

  • Participant or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements
  • Participant has been implanted with the Micra AV2 device or is intended to receive or be treated with an eligible Micra AV2 device as per standard of care.
  • Participants with a history of paroxysmal atrial fibrillation undergoing Micra AV2 implantation, as per standard of care.
  • Age 18-85 years old with the ability to consent for the procedure
  • Participant is consented within the enrollment window of the therapy received, as applicable
  • English Speaking

Exclusion criteria

Exclusion Criteria:

  • Participant who is, or is expected to be, inaccessible for follow-up
  • Participation is excluded by local law
  • Participant is currently enrolled or plans to enroll in concurrent drug/device study that may confound the study results
  • Participant with persistent/chronic atrial fibrillation
  • Prisoner or cognitively impaired due to the study procedures involving independent wearing of the holter monitor for research purposes.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Interventions

  • DeviceMicra AV2- Observational

    All eligible patients that have a history of paroxysmal atrial fibrillation and an indication to undergo Micra AV2 device placement as per standard of care (SOC) across the participating sites within the Northwell Health System can be included in this analysis. Micra AV2 placement indications will be at the discretion of the treating electrophysiologist, but are expected to be predominantly atrioventricular block.

06

What researchers measure

Primary outcomes

  1. To evaluate the prevalence of atrial fibrillation in the Micra AV2 patients

    Time frame: Through study completion, an average of 6 months

  2. To evaluate A4 amplitude trend changes during sinus rhythm and atrial fibrillation

    To evaluate the presence of paroxysmal atrial fibrillation and the degree to which atrial activity and A4 amplitude trend changes will be assessed using a designated Medtronic Research Holter monitor that detects Micra AV2 signals at any point in the study during episodes of sinus rhythm and atrial fibrillation.

    Time frame: Through study completion, an average of 6 months

  3. To determine the ability of the Micra AV2 device to detect the presence and burden of atrial fibrillation

    Micra AV2 placement indications will be at the discretion of the treating electrophysiologist, but are expected to be predominantly atrioventricular block. Periodic device interrogations will be reviewed for the presence of effective atrial tracking during sinus rhythm.

    Time frame: Through study completion, an average of 6 months

07

Study locations

1 of 1 sites recruiting
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07344961
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Dec 29, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 4, 2026

Study contacts

Salome Elia Reddy, PhD
Contact
seliareddy@northwell.edu
516-600-1459
Emma Grace Lao
Contact
elao1@northwell.edu
516-881-7037
Haisam Ismail, MD
principal investigator · Northwell Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion